But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar ...

Merck's two most important growth drivers are encountering headwinds now. While they are manageable, the company's mid-term prospects aren't strong. Merck's biggest growth drivers are cancer drug ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

Merck MRK will report its second-quarter 2025 earnings on July 29, before market open. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $15.77 billion and $1.99 per ...

This was the stock's second consecutive day of losses.